Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Cue Biopharma (NASDAQ:CUE) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments [Yahoo! Finance]
Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments
Cue Biopharma GAAP EPS of -$0.07 beats by $0.02, revenue of $2.15M misses by $0.14M [Seeking Alpha]